Trial | Age | μ | ± sd | CVp | S 2 fam | S 2 Res | CVg | h2i (se) |
---|---|---|---|---|---|---|---|---|
CHA | 7 | 18.2 | 8.6 | 0.47 | 5.3 | 69.6 | 0.13 | 0.28 (0.08) |
COR | 7.0 | 4.9 | 0.70 | 0.9 | 23.0 | 0.13 | 0.15 (0.06) | |
FOR | 7.4 | 5.2 | 0.69 | 0.6 | 26.0 | 0.10 | 0.09 (0.04) | |
FRI | 8.7 | 5.9 | 0.68 | 0.7 | 34.1 | 0.10 | 0.09 (0.05) | |
MAN | 6.5 | 4.7 | 0.72 | 0.67 | 21.6 | 0.13 | 0.12 (0.05) | |
NOC | 2.5 | 2.2 | 0.89 | 0.11 | 4.67 | 0.13 | 0.09 (0.04) | |
REB | 14.8 | 6.1 | 0.41 | 1.69 | 35.9 | 0.09 | 0.18 (0.06) | |
CHA | 12 | 67.0 | 29.9 | 0.45 | 49.9 | 848 | 0.11 | 0.25 (0.07) |
COR | 90.1 | 49.3 | 0.55 | 152 | 2.28·103 | 0.14 | 0.25 (0.07) | |
FOR | 36.9 | 19.9 | 0.54 | 8.19 | 386 | 0.08 | 0.08 (0.04) | |
FRI | 68.6 | 31.6 | 0.46 | 24.7 | 971 | 0.07 | 0.10 (0.05) | |
MAN | 29.7 | 14.9 | 0.50 | 5.64 | 216 | 0.08 | 0.10 (0.04) | |
NOC | 80.9 | 44.0 | 0.54 | 78.6 | 1.86·103 | 0.11 | 0.16 (0.05) | |
REB | 170 | 65.0 | 0.38 | 108 | 4.12·103 | 0.06 | 0.10 (0.04) | |
CHA | 17 | 265 | 124 | 0.47 | 831 | 1.45·104 | 0.11 | 0.22 (0.07) |
FOR | 74.1 | 46.8 | 0.63 | 49.4 | 2.14·103 | 0.09 | 0.09 (0.05) | |
FRI | 188 | 86.8 | 0.46 | 297 | 7.25·103 | 0.09 | 0.16 (0.06) | |
MAN | 87.8 | 49.9 | 0.57 | 58.8 | 2.43·103 | 0.09 | 0.09 (0.04) |